Webcast scheduled to begin at 7:00 a.m. CDT on Monday, June 2, 2008
PRINCETON, N.J., May 16 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) is scheduled to host a webcast review and discussion of the
ipilimumab data presented during the Annual Meeting of the American Society
of Clinical Oncology (ASCO) in Chicago. The live webcast will begin at 7:00
a.m. CDT on Monday, June 2, 2008. The webcast can be accessed on Medarex's
website at http://www.medarex.com and will be archived and available for replay
for at least 14 days.
Additional or updated data beyond the information submitted in the
abstracts may be included in the following presentations at ASCO:
Ipilimumab Presentations in Melanoma
-- "Antitumor response and new lesions in advanced melanoma patients on
ipilimumab treatment" (Abstract #3020, Developmental Therapeutics:
Immunotherapy Session) - Poster presentation and discussion from
2:00 p.m. to 6:00 p.m. local time on Friday, May 30, 2008.
-- "Long-term survival of patients with advanced melanoma who received
ipilimumab administered at 10mg/kg every 3 weeks for 4 doses (induction
dosing)" (Abstract #3018, Developmental Therapeutics: Immunotherapy
Session) - Poster presentation and discussion from 2:00 p.m. to
6:00 p.m. local time on Friday, May 30, 2008.
-- "Potential immune biomarkers of gastrointestinal toxicities and
efficacy in patients with advanced melanoma treated with ipilimumab
with or without prophylactic budesonide" (Abstract #3022, Developmental
Therapeutics: Immunotherapy Session) - Poster presentation and
discussion from 2:00 p.m. to 6:00 p.m. local time on Friday, May 30,
2008.
-- "Novel efficacy criteria for antitumor activity to immunotherapy using
the example of ipilimumab, an anti-CTLA-4 monoclonal antibody"
(Abstract #3008, Developmental Therapeutics: Immunotherapy Session) -
Oral presentation beginning at 4:30 p.m. local time one Saturday, May
31, 2008.
-- "Effect of prior treatment status on the efficacy and safety of
ipilimumab monotherapy in treatment-naive and previously treated
patients with advanced melanoma" (Abstract #9055, Melanoma Session) -
Poster presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday,
May 31, 2008.
-- "An analysis of the effectiveness of specific guidelines for the
management of ipilimumab-mediated diarrhea/colitis: prevention of
gastrointestinal perforation and/or colectomy" (Abstract #9063,
Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.
local time on Saturday, May 31, 2008.
-- "Model-based evaluation of ipilimumab dosage regimen in patients with
advanced melanoma" (Abstract #9073, Melanoma Session) - Poster
presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May
31, 2008.
-- "Safety and efficacy of ipilimumab with or without prophylactic
budesonide in treatment-naive and previously treated patients with
advanced melanoma" (Abstract #9010, Melanoma Session) - Oral
presentation beginning at 10:15 a.m. local time on Sunday, June 1,
2008.
-- "Efficacy and safety of ipilimumab induction and maintenance dosing in
patients with advanced melanoma who progressed on one or more prior
therapies" (Abstract #9021, Melanoma Session) - Poster presentation and
discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,
2008.
-- "Disease control and long-term survival in chemotherapy-naive patients
with advanced melanoma treated with ipilimumab (MDX-010) with or
without dacarbazine" (Abstract #9022, Melanoma Session) - Poster
presentation and discussion from 2:00 p.m. to 6:00 p.m. local time on
Sunday, June 1, 2008.
-- "Dose effect of ipilimumab in patients with advanced melanoma: results
from a phase 2, randomized, dose-ranging study" (Abstract #9025,
Melanoma Session) - Poster presentation and discussion from 2:00 p.m.
to 6:00 p.m. local time on Sunday, June 1, 2008.
-- "Prolonged survival in objective responders to ipilimumab therapy"
(Abstract #20004) - Publication only.
Ipilimumab Presentations in Prostate Cancer
-- "Phase 1 trial of ipilimumab (IPI) alone and in combination with
radiotherapy (XRT) in patients with metastatic castration resistant
prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for
Patients with Prostate Cancer Session) - Oral presentation beginning at
11:30 a.m. local time on Monday, June 2, 2008.
-- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate
cancer and ipilimumab in patients with metastatic hormone-refractory
prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)
- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on
Saturday, May 31, 2008.
Additional Presentations at ASCO
-- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal
antibody, in patients with selected refractory or relapse malignancies"
(Abstract #3006, Developmental Therapeutics: Immunotherapy Session) -
Oral presentation beginning at 4:00 p.m. local time on Saturday, May
31, 2008.
-- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in
combination with ixabepilone in preclinical tumor models" (Abstract
#3048, Developmental Therapeutics: Immunotherapy Session) - Poster
presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1,
2008.
-- "Effect of a fully human anti-CD70 antibody on apoptosis and
dephosphorylation of MAPK proteins in chronic lymphocytic leukemia"
(Abstract #3073, Developmental Therapeutics: Immunotherapy Session) -
Poster presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday,
June 1, 2008.
More information about the ASCO Annual Meeting may be found at
http://www.asco.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex Statement on Cautionary Factors
Except for the historical information presented herein, the statements
relating to Medarex's advances related to its products in this press
release may constitute forward-looking statements, as defined in the
Private Securities Litigation Reform Act of 1995, that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed
or implied by such statements. Medarex disclaims, however, any intent or
obligation to update these forward-looking statements. Risks and
uncertainties include risks associated with product discovery and
development, uncertainties related to the outcome of clinical trials,
slower than expected rates of patient recruitment, unforeseen safety issues
resulting from the administration of antibody products in patients,
uncertainties related to product manufacturing, the need for additional
capital, compliance with regulatory requirements, risks associated with the
use of hazardous substances and risks associated with the enforceability of
our patents as well as risks detailed from time to time in Medarex's public
disclosure filings with the U.S. Securities and Exchange Commission (SEC),
including its Annual Report on Form 10-K for the fiscal year ended December
31, 2007 and its Quarterly Report on Form 10-Q for the quarter ended March
31, 2008. There can be no assurance that such development efforts will
succeed or that developed products will receive required regulatory
clearance or that, even if such regulatory clearance were received, such
products would ultimately achieve commercial success. Copies of Medarex's
public disclosure filings are available from its investor relations
department.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.asco.org
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216, or Nichol Harber, Corporate
Communications (media), +1-609-430-2880, x2214
|
